{u'keywords': [u'Servier', u'GenRx', u'brand substitution', u'Coversyl', u'stamp', u'standard form', u'doctors', u'Servier submits', u'doctor', u'advertisement', u'product', u'improved stability', u'generic substitution', u'standard form prescription', u'superior product performance', u'stamps', u'GenRx perindopril product', u'Medical Observer', u'generic form', u'banner advertisement', u'interlocutory relief', u'erbumine salt', u'market share', u'GenRx submits', u'new Coversyl arginine', u'box', u'patients', u'evidence', u'proceedings', u'interlocutory injunction', u'market generic perindopril', u'Servier sale team', u'application', u'prescription form', u'GenRx products', u'advertisements', u'single prescription form', u'generic product', u'perindopril erbumine salt', u'Medicare Australia prescription', u'advertising prescription pharmaceuticals', u'perindopril products', u'Australian market', u'generic company', u'Trade Practices Act', u'pharmacist', u'Pharmaceutical Benefits Scheme', u'medical trade publication', u'allied health professionals'], u'casename': u'GenRx Pty Limited v Les Laboratoires Servier [2007] FCA 442 (26 March 2007)', u'filename': u'training_data/07_442.xml'}